Menu Close

Medicare mulls coverage for controversial Alzheimer’s drug

(Healthday)—Medicare launched a formal process on Monday that will determine whether the agency will cover Aduhelm, the newly approved Alzheimer’s drug whose high price tag and unproven benefits have prompted widespread controversy.